Cargando…
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is requi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690724/ https://www.ncbi.nlm.nih.gov/pubmed/33114033 http://dx.doi.org/10.3390/diagnostics10110864 |
_version_ | 1783614133890973696 |
---|---|
author | Olah, Csilla Tschirdewahn, Stephan Hoffmann, Michèle J. Krafft, Ulrich Hadaschik, Boris Nyirady, Peter Szendröi, Attila Módos, Orsolya Csizmarik, Anita Kovalszky, Ilona Reis, Henning Szarvas, Tibor |
author_facet | Olah, Csilla Tschirdewahn, Stephan Hoffmann, Michèle J. Krafft, Ulrich Hadaschik, Boris Nyirady, Peter Szendröi, Attila Módos, Orsolya Csizmarik, Anita Kovalszky, Ilona Reis, Henning Szarvas, Tibor |
author_sort | Olah, Csilla |
collection | PubMed |
description | Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC1) tissue expression and serum concentration may be associated with cisplatin resistance. Thus, pre-treatment serum levels of SDC1 and its expression in chemo-naïve tissues were assessed in 121 muscle-invasive bladder cancer patients who underwent postoperative platinum-based chemotherapy. SDC1 concentrations were evaluated by ELISA in 52 baseline and 90 follow-up serum samples and tissue expressions were analyzed by immunohistochemistry in an independent cohort of 69 formalin-fixed paraffin-embedded tumor samples. Pre-treatment SDC1 serum levels were significantly higher in lymph node metastatic (p = 0.009) and female patients (p = 0.026). SDC1 tissue expression did not correlate with clinicopathological parameters. High pre-treatment SDC1 serum level and the presence of distant metastasis were independent risk factors for overall survival (Hazard ratio (HR): 1.439, 95% Confidence interval (CI): 1.003–2.065, p = 0.048; HR: 2.269, 95%CI: 1.053–4.887, p = 0.036). Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients. Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making. |
format | Online Article Text |
id | pubmed-7690724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76907242020-11-27 Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients Olah, Csilla Tschirdewahn, Stephan Hoffmann, Michèle J. Krafft, Ulrich Hadaschik, Boris Nyirady, Peter Szendröi, Attila Módos, Orsolya Csizmarik, Anita Kovalszky, Ilona Reis, Henning Szarvas, Tibor Diagnostics (Basel) Article Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC1) tissue expression and serum concentration may be associated with cisplatin resistance. Thus, pre-treatment serum levels of SDC1 and its expression in chemo-naïve tissues were assessed in 121 muscle-invasive bladder cancer patients who underwent postoperative platinum-based chemotherapy. SDC1 concentrations were evaluated by ELISA in 52 baseline and 90 follow-up serum samples and tissue expressions were analyzed by immunohistochemistry in an independent cohort of 69 formalin-fixed paraffin-embedded tumor samples. Pre-treatment SDC1 serum levels were significantly higher in lymph node metastatic (p = 0.009) and female patients (p = 0.026). SDC1 tissue expression did not correlate with clinicopathological parameters. High pre-treatment SDC1 serum level and the presence of distant metastasis were independent risk factors for overall survival (Hazard ratio (HR): 1.439, 95% Confidence interval (CI): 1.003–2.065, p = 0.048; HR: 2.269, 95%CI: 1.053–4.887, p = 0.036). Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients. Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making. MDPI 2020-10-23 /pmc/articles/PMC7690724/ /pubmed/33114033 http://dx.doi.org/10.3390/diagnostics10110864 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Olah, Csilla Tschirdewahn, Stephan Hoffmann, Michèle J. Krafft, Ulrich Hadaschik, Boris Nyirady, Peter Szendröi, Attila Módos, Orsolya Csizmarik, Anita Kovalszky, Ilona Reis, Henning Szarvas, Tibor Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
title | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
title_full | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
title_fullStr | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
title_full_unstemmed | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
title_short | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
title_sort | soluble syndecan-1 levels are associated with survival in platinum-treated bladder cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690724/ https://www.ncbi.nlm.nih.gov/pubmed/33114033 http://dx.doi.org/10.3390/diagnostics10110864 |
work_keys_str_mv | AT olahcsilla solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT tschirdewahnstephan solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT hoffmannmichelej solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT krafftulrich solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT hadaschikboris solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT nyiradypeter solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT szendroiattila solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT modosorsolya solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT csizmarikanita solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT kovalszkyilona solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT reishenning solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT szarvastibor solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients |